Circulating Tumour DNA To Monitor Treatment Response And Resistance In Chronic Lymphocytic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$876,950.00
Summary
Many cancers shed small amounts of DNA (ctDNA) into the patient’s bloodstream and recent advances in genomic technologies now allow levels of ctDNA to be accurately measured in the blood. Changes in ctDNA levels have potential to be used as specific markers of disease progression and/or response to cancer therapy. This project will evaluate if ctDNA can be used to monitor treatment responses and individualise treatment decisions in patients with chronic lymphocytic leukaemia.
Optimising Early Interventions For Young People With Emerging Mood Disorder
Funder
National Health and Medical Research Council
Funding Amount
$2,653,052.00
Summary
One of our greatest health challenges is to develop highly-personalised interventions for teenagers and young adults with emerging mood disorders, like major depression or bipolar disorder. This new Australian centre combines our national expertise and links it with research innovation and training in key European and North American centres. It tests the viability of selecting the best treatments for young people with mood disorders on the basis of novel genetic, neuropsychological, circadian, i ....One of our greatest health challenges is to develop highly-personalised interventions for teenagers and young adults with emerging mood disorders, like major depression or bipolar disorder. This new Australian centre combines our national expertise and links it with research innovation and training in key European and North American centres. It tests the viability of selecting the best treatments for young people with mood disorders on the basis of novel genetic, neuropsychological, circadian, imaging, immunological or clinical methods.Read moreRead less
Deadly Commute - Targeting The Trafficking Mechanisms That Licence Inflammatory Cell Death
Funder
National Health and Medical Research Council
Funding Amount
$774,544.00
Summary
MLKL is a protein naturally found inside cells. MLKL is activated by inflammation. Once activated, MLKL relocates to the outer periphery of cells and kills them. Gut cells are especially vulnerable to death-by-MLKL and this problem causes Inflammatory Bowel Disease. Using cutting edge microscopy, we have discovered how MLKL moves to the periphery of cells prior to killing them. We will test if blocking this movement of MLKL to the cell periphery stops gut death and Inflammatory Bowel Disease.